DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
CNBC's Arabile Gumede - 1 Nikos Pekiaridis - 1 AstraZeneca - 1 Susan Galbraith - 1
Top related locs:
Shanghai China Europe London Singapore U.K Swedish U.S
Top related orgs:
AstraZeneca - 3 Fusion Pharmaceuticals Inc - 2 Astrazeneca - 1 Artificial Intelligence - 1 — Pharmaceutical - 1 CNBC - 1 U.S . FDA - 1 Pharmaceuticals - 1

Search resuls for: "Fusion Pharmaceuticals Inc"


3 mentions found


☆ AstraZeneca targets $80 billion in total revenue by 2030 in 'post-Covid era'
  + stars: | 2024-05-21 | by ( Sophie Kiderlin | In | ) www.cnbc.com   time to read: +2 min
Costfoto | Future Publishing | Getty ImagesLONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. AstraZeneca will focus on its oncology, biopharmaceuticals and rare diseases businesses and expects to release an additional 20 medicines in the next six years. "Many of them have the potential to be $5 billion drugs," Sarin noted. A company statement detailed that this revenue figure could be hit annually for many of the new medicines in peak years. "For the entire market to get replaced it will take time, but we think we have the technology today to start replacing them," Sarin told CNBC.
Persons: CNBC's Arabile Gumede Organizations: Astrazeneca, Artificial Intelligence, — Pharmaceutical, AstraZeneca, CNBC, U.S . FDA, Pharmaceuticals, Investments Locations: Shanghai, China, Europe, London, Singapore
☆ AstraZeneca to withdraw Covid vaccine worldwide, citing a drop in demand
  + stars: | 2024-05-08 | by ( Sophie Kiderlin | In | ) www.cnbc.com   time to read: +2 min
In this photo illustration a covid-19 vaccine is seen with the AstraZeneca logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined. Demand for the Vaxzevria vaccine has tailed off as new vaccines tailored to specific Covid variants have emerged, AstraZeneca said in a statement. "As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines. Next to Covid vaccines, AstraZeneca has been working on a range of other treatments for illnesses including cancer.
Persons: Nikos Pekiaridis Organizations: AstraZeneca, Getty Images, Pharmaceutical, University of Oxford, Covid, World Health Organization, European Union, Fusion Pharmaceuticals Inc Locations: U.K
☆ AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase
  + stars: | 2024-03-19 | by ( ) www.cnbc.com   time to read: +2 min
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. Fusion is developing "next-generation" radioconjugates (RCs) to treat cancer. RCs deliver a radioactive isotope directly to cancer cells through precise targeting using molecules and have emerged as a promising modality in cancer treatment over recent years, AstraZeneca said. Radiotherapy and chemotherapy have been the mainstays of cancer treatment for decades.
Persons: AstraZeneca, Susan Galbraith Organizations: Fusion Pharmaceuticals Inc, Amolyt Pharma, AstraZeneca, Fusion, Oncology, U.S . Food, Drug Administration, FDA Locations: Swedish, U.S, radioconjugates
0 next >>
Total: 3